Cooley LLP

A Cooley team advised Engage Bio, a preclinical biotechnology company pioneering non-viral DNA delivery, on its acquisition by Eli Lilly for up to $202 million in cash, including an upfront payment and subsequent payments upon achievement of specified development milestones. Congratulations to Engage Bio and to the Cooley team led by Charity Williams, Lindsey O'Crump, Mika Reiner Mayer and Lauren Creel, with support from Nitasha Bennett, Alessandra Murata, Josh Himmelstern, Allie Pilmer, Camille Awono, Emily Iannarelli, Ross Eberly, Jonathan Rivinus, Freddy Yip, Stacey Bradford, Megan Browdie, Paula Fleckenstein, Tony Guan, Andrew Epstein, Morgan (Gough) Perna and Karen Tsai. ➡️ Read more here: https://bit.ly/3RAELrX

For more than six consecutive years, Cooley has secured the #1 spot in the US and globally for representing companies raising venture capital, according to PitchBook’s Q1 2026 Global League Tables. The publication noted Cooley as #1 for representing: ✅ Companies in the US and globally. ✅ All clients in the combination of venture capital financings, IPOs, M&A and PE transactions. ✅ Venture capital financings in several industry sectors and geographic regions. LSEG’s Global Venture Capital Review additionally spotlighted Cooley as the #1 firm for: ✅ Representing companies raising venture capital based on deal count. ✅ Venture capital firm representations based on overall deal count and overall deal value. Congratulations to Team Cooley and thank you to our clients for your continued trust in us! Read more: https://bit.ly/3RjPEyr

💡 Read this Law.com article to hear from Cooley partner Will Pao, as he dives into how Chinese companies’ approach to US litigation and regulatory scrutiny has evolved over 20 years: https://bit.ly/4uLRd6x

💡Learn how Cooley’s experienced, agile legal team gave HawkEye 360's management the bandwidth to keep business on track while executing three transactions: https://bit.ly/3PLnImB

A Cooley team advised Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, on its $690 million aggregate principal amount of convertible senior notes due 2032 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90 million aggregate principal amount of the notes. Congratulations to Mirum and to the Cooley team led by Jason Kent, Mischi aMarca, Jason Savich, Julia Rohm-Ensing Boesch, Timothy Nguyen, Nicholaus Johnson, Kelly McCormick, Yoni Horn and Rebeca Kinslow. 👉 Read more here: https://bit.ly/3RhBvlk

We are excited to welcome Meredith Halama and Katie Baldwin Cramer, who have joined the firm in our global cyber/data/privacy group. They are among the industry’s foremost leaders in the application of consumer privacy laws to advertising technology. Together, Meredith and Katie enhance the litigation department’s cyber/data/privacy practice, which is already recognized as among the industry’s best, and reinforce its capabilities to serve major technology companies. Meredith and Katie will reside in the firm’s Washington, DC, and Denver offices, respectively. Read more: https://bit.ly/4nC1gZz

A Cooley team – led by Rodrigo Seira Silva-Herzog and Connor Tweardy – advised Circle Internet Group, Inc., a full-stack internet financial platform business, on its $222 million presale of the ARC token, at a $3 billion fully diluted network valuation. Circle’s ARC presale is the first ever token sale by an SEC-registered company. Congratulations, all. ➡️ Read more here: https://bit.ly/4eTmrUP

Cooley advised Orphai Therapeutics, a clinical-stage biotechnology company, on its sale to Quince Therapeutics, a biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. The acquisition brings Orphai’s lead program LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), to treat rare pulmonary diseases, into Quince’s pipeline. Congratulations to Orphai and to the Cooley team led by Brittany Wightman, Madison Jones, Rita Sobral, Rama Padmanabhan, Ariel Rom, Kyle Hess, Dillon Holdsworth, Susan Choy, John DelMastro and Mac Taggart, with support from Ariane A., Nyron Persaud, Mark Cornillez-Ty, Breanna Qin, Charity Williams, John Forrest, Joseph Perry, Noah Goldman, Jeff Tolin, Hardy Zhou, Andrew Epstein, Christopher Suhler, Ross Eberly, Jacob Lahana and Alyssa Broer. 👉 Read more here: https://bit.ly/3PLMRgY

Check out our latest Market Talks webinar to hear from partner David Peinsipp as he shares insights on market momentum, particularly as we head into the second half of the year. 🎥 View the full replay: https://bit.ly/4wwh0kY

Cooley advised Delos Capital, a life sciences investment firm that empowers life sciences leaders to turn bold ideas into medical breakthroughs for patients, on its strategic collaboration with AP Biosciences to create and incubate new biotechnology companies. Congratulations to Delos and to the Cooley team led by James Schneider, J. Brian Stalter and Arda Can Tekin. ➡️ Read more here: https://bit.ly/3PtO0cN